Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13411699 | 0.90 | KMT2A (0.52) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL6289746 | 0.89 | MEN1 (0.44) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL14984056 | 0.89 | EPHX1 (0.47) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL19171879 | 0.88 | KMT2A (0.48) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL6289721 | 0.87 | KMT2A (0.43) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL26669195 | 0.86 | EPHX2 (0.51) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL6283536 | 0.86 | MEN1 (0.41) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL22526230 | 0.85 | MEN1 (0.44) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL1415863 | 0.85 | EPHX2 (0.45) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL6290266 | 0.85 | MEN1 (0.44) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | NHERF1, SLC9A3, SLC26A3 | MEN1 2007/4885KMT2A 1917/4885EPHX2 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.